BCCA Protocol Summary for Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder, Pancreas Carcinoma and Cholangiocarcinoma) and Metastatic Anal using Infusional Fluorouracil and CI(S)platin

**Protocol Code**
GIFUC

**Tumour Group**
Gastrointestinal

**Contact Physician**
GI Systemic Therapy

**ELIGIBILITY:**
- Metastatic or unresectable adenocarcinoma of the upper gastrointestinal tract (stomach, esophagus, gall bladder, pancreas, bile ducts)
- Metastatic squamous cell or cloacogenic carcinoma of the anal canal
- Metastatic esophageal squamous cell carcinoma
- ECOG 0 to 2

**EXCLUSIONS:**
- CNS metastases
- Uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the preceding 6 months, serious uncontrolled cardiac dysrhythmia
- Inadequate hepatic function (total bilirubin greater than 35 micromol/L, AST greater than 3x normal)
- Inadequate renal function (creatinine clearance less than 45 ml/min as calculated by Cockcroft/Gault formula – see page 3)

**TESTS:**
- Baseline: CBC, diff and platelets, creatinine, bilirubin and AST
- Prior to each treatment: CBC, diff and platelets, creatinine
- If clinically indicated: bilirubin, appropriate imaging studies
- For patients on warfarin, weekly INR during fluorouracil therapy until stable warfarin dose established, then INR prior to each cycle.

**PREMEDICATIONS:**

This regimen is high moderate in emetogenic potential. See SCNAUSEA protocol.

**TREATMENT:**

A cycle equals -

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI(S)platin</td>
<td>25 mg/m²</td>
<td>IV in 100 mL NS over 30 min</td>
</tr>
<tr>
<td>Fluorouracil (5FU)</td>
<td>1000 mg/m²/day for 2 days (total dose = 2000 mg/m² over 48 h)</td>
<td>IV in D5W to a total volume of 96 mL by continuous infusion at 2 mL/h via appropriate infusor device*</td>
</tr>
</tbody>
</table>

*For total dose greater than 4600 mg, to a total volume of 240 mL by continuous infusion at 5 mL/h.

*(Inpatients: 1000 mg/m²/day in 1000 mL D5W by continuous infusion daily over 24 h for 2 days)*

Patients with PICC lines should have a weekly assessment of the PICC site for evidence of infection or thrombosis.
Repeat every 7 days for 12 weeks. One cycle = 1 week. (maximum = 24 cycles). Most responding patients will manifest benefit by 6 to 8 cycles.

**DOSE MODIFICATIONS:**

1. **Hematological:**

<table>
<thead>
<tr>
<th>ANC (x10^9/L)</th>
<th>Platelets (x10^9/L)</th>
<th>Dose (both drugs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.0 and greater than or equal to 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>less than 1.0 or less than 100</td>
<td>delay</td>
<td></td>
</tr>
</tbody>
</table>

2. **Renal dysfunction:**

   Delay for one week if serum creatinine greater than 3 x ULN. If serum Creatinine less than 3 x ULN adjust CISplatin dose as follows:

<table>
<thead>
<tr>
<th>Creatinine Clearance (by Cockcroft/Gault formula)</th>
<th>Dose - CISplatin only</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 60 ml/min</td>
<td>100%</td>
</tr>
<tr>
<td>45 – 59 ml/min</td>
<td>50%</td>
</tr>
<tr>
<td>less than 45 ml/min</td>
<td>delay</td>
</tr>
</tbody>
</table>

   *Cockcroft/Gault formula:*

   \[
   CrCl = \frac{N (140 - \text{age}) \times \text{weight (kg)}}{\text{serum creatinine (micromol/L)}}
   \]

   *Where N = 1.04 for females, and 1.23 for males*

3. **Gastrointestinal toxicity:**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Stomatitis</th>
<th>Diarrhea</th>
<th>Dose Fluorouracil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Painless ulcers, erythema or mild soreeness</td>
<td>Increase of 2 to 3 stools/day or nocturnal stools; or moderate increase in loose watery colostomy output</td>
<td>100%</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Painful erythema, edema, or ulcers but can eat</td>
<td>Increase of 4 to 6 stools/day, or nocturnal stools or moderate increase in loose watery colostomy output</td>
<td>75%</td>
</tr>
</tbody>
</table>
| Grade 3 or 4 | As above, but cannot eat, mucosal necrosis, requires parenteral support. | Increase of greater than 7 stools/day or grossly bloody diarrhea, or incontinence, malabsorption; or severe increase in loose watery colostomy output requiring parenteral support | Discontinue or delay until toxicity resolved then resume at 50%.

4. **Hand-Foot Syndrome**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Hand-Foot Syndrome</th>
<th>Dose Fluorouracil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Skin changes or dermatitis without pain e.g. erythema, peeling</td>
<td>100%</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Skin changes with pain not interfering with function</td>
<td>75% until resolved then consider increasing dose by 10%</td>
</tr>
<tr>
<td>Grade 3</td>
<td>Skin changes with pain, interfering with function</td>
<td>Delay until resolved then resume at 75%</td>
</tr>
</tbody>
</table>

5. **Hepatic dysfunction:** Omit treatment if bilirubin greater than 85 micromol/L unless secondary to biliary obstruction. Refer to BCCA Cancer Drug Manual.
PRECAUTIONS:

1. **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated aggressively.
2. **Renal Toxicity**: Nephrotoxicity is common with CISplatin. Encourage oral hydration. Avoid nephrotoxic drugs such as aminoglycoside antibiotics.
3. **Myocardial** ischemia and angina occurs rarely in patients receiving fluorouracil or capecitabine. Development of cardiac symptoms including signs suggestive of ischemia or of cardiac arrhythmia is an indication to discontinue treatment. If there is development of cardiac symptoms patients should have urgent cardiac assessment. Generally re-challenge with either fluorouracil or capecitabine is not recommended as symptoms potentially have a high likelihood of recurrence which can be severe or even fatal. Seeking opinion from cardiologists and oncologists with expert knowledge about fluorouracil / capecitabine toxicity is strongly advised under these circumstances. The toxicity should also be noted in the patient’s allergy profile.
4. **Diarrhea**: Patients should report mild diarrhea that persists over 24 hours or moderate diarrhea (4 stools or more per day above normal, or a moderate increase in ostomy output). Mild diarrhea can be treated with loperamide (eg. IMODIUM®) following the manufacturer’s directions or per the BCCA Guidelines for Management of Chemotherapy-Induced Diarrhea. Note that diarrhea may result in increased INR and the risk of bleeding in patients on warfarin.
5. **Dihydropyrimidine dehydrogenase (DPD) deficiency** may result in severe and unexpected toxicity – stomatitis, diarrhea, neutropenia, neurotoxicity – secondary to reduced drug metabolism. This deficiency is thought to be present in about 3% of the population.
6. **Possible drug interaction with fluorouracil and warfarin** has been reported and may occur at any time. For patients on warfarin, weekly INR during fluorouracil therapy is recommended until a stable warfarin dose is established. Thereafter, INR prior to each cycle. Consultation to cardiology/internal medicine should be considered if difficulty in establishing a stable warfarin dose is encountered. Upon discontinuation of fluorouracil, repeat INR weekly for one month.
7. **Possible drug interaction with fluorouracil and phenytoin and fosphenytoin** has been reported and may occur at any time. Close monitoring is recommended. Fluorouracil may increase the serum concentration of these two agents.

Call the GI Systemic Therapy physician at your regional cancer centre or Dr. JP McGhie at (250) 519-5500 or 1-800-670-3322 with any problems or questions regarding this treatment program.

Date activated: N/A

Date revised: 1 Nov 2015 (addition of Diarrhea Precaution)